Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

FTAI Aviation is an integrated full-service provider of aftermarket power and maintenance for commercial jet engines. In its Q3 2024 financial report, FTAI Aviation reported quarterly revenue in its ...

Alzheimer’s Therapeutics MarketThe global Alzheimer’s therapeutics market is projected to experience significant growth, with an expected valuation of USD 3,052.3 million in 2023. The market is ...

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...

January 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for ...

County commissioners distributed over $700,000 to addiction recovery and treatment programs from national opioid misuse ...